» Articles » PMID: 10073601

The Intrarenal Vascular Lesions Associated with Primary Antiphospholipid Syndrome

Overview
Specialty Nephrology
Date 1999 Mar 12
PMID 10073601
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Even 10 yr after the identification of the antiphospholipid syndrome (APS), renal involvement in the course of APS is still relatively unrecognized, and is probably underestimated. The association of anticardiolipin antibodies and/or lupus anticoagulant with the development of a vaso-occlusive process involving numerous organs is now confirmed. In a multicenter study, 16 cases of "primary" APS (PAPS) were found and followed for 5 yr or more, all with renal biopsy. In all 16 cases of PAPS, there was a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries (12 patients), recanalizing thrombi in arteries and arterioles (six patients), and focal cortical atrophy (10 patients). In combination, these led to progressive destruction of the kidney, accelerated by acute glomerular and arteriolar microangiopathy in five patients. Focal cortical atrophy is a distinctive lesion, present in 10 biopsies, and likely represents the histologic and functional renal analogue to the multiple cerebral infarcts detected on imaging studies. The clinical hallmark of this vascular nephropathy in PAPS is systemic hypertension, only variably associated with renal insufficiency, proteinuria, or hematuria. The ensemble of histologic renal lesions defined in this study should aid in the separation of the lesions found in cases of secondary APS, especially systemic lupus erythematosus, into those lesions related to APS and those related to the underlying disease.

Citing Articles

Endothelial Dysfunction Biomarkers and CKD Incidence in the REGARDS Cohort.

Short S, Wilkinson K, Long D, Crews D, Gutierrez O, Irvin M Kidney Int Rep. 2024; 9(7):2016-2027.

PMID: 39081743 PMC: 11284378. DOI: 10.1016/j.ekir.2024.04.056.


Rethinking antiphospholipid syndrome to guide future management and research.

Knight J, Erkan D Nat Rev Rheumatol. 2024; 20(6):377-388.

PMID: 38702511 DOI: 10.1038/s41584-024-01110-y.


Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations.

Gaspar P, Sciascia S, Tektonidou M Rheumatology (Oxford). 2024; 63(SI):SI24-SI36.

PMID: 38320589 PMC: 10846913. DOI: 10.1093/rheumatology/kead571.


Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature.

Taghavi M, Jabrane A, Jacobs L, Mesquita M, Demulder A, Nortier J Antibodies (Basel). 2024; 13(1).

PMID: 38247565 PMC: 10801604. DOI: 10.3390/antib13010001.


Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation.

Jiang H, Shi Y, Liu W, Liu B, Chen Y, Zhou Y RMD Open. 2024; 10(1).

PMID: 38176738 PMC: 10773434. DOI: 10.1136/rmdopen-2023-003664.